

SCIENTIFIC PROGRAMME

77

09.00 – 10.30

Room: Cheops

S25: Innovations in Blood Transfusion

Moderators: H. Goubran, R. Henschler

09.00 – 09.30

4A-S25-01 INTERNATIONAL RARE BLOOD DONOR CENTER

S. Nance (American Red Cross, Philadelphia, USA)

09.30 – 10.00

4A-S25-02 BLOOD-DERIVED BIOMATERIALS: FIBRIN SEALANT, PLATELET GEL AND PLATELET FIBRIN GLUE

T. Burnouf, C.Y. Su, M. Radosevich, H. Goubran, M. El-Ekiaby (Human Protein Process Sciences, Lille, France)

10.00 – 10.30

4A-S25-03 PROTEOMICS AND BLOOD TRANSFUSION

G.M. Liumbruno, G.M. D'Amici, L. Zolla, G. Grazzini (Italian National Blood Centre; San Giovanni Calibita Fatebenefratelli Hospital, Rome, Italy)

SCIENTIFIC PROGRAMME

09.00 – 10.30

Room: Mycerinos

S26: Donor Adverse Events

Moderators: J. Jørgensen, J. Wiersum-Osselton

09.00 – 09.30

4A-S26-01 FAINT AND PRE-FAINT REACTIONS IN WHOLE BLOOD DONORS: PREDICTIVE VALUE OF PRE-DONATION MEASUREMENTS

P. Tomasulo (Blood Systems Inc., Scottsdale, USA)

09.30 – 09.45

4A-S26-02 THE SPECTRUM OF ADVERSE REACTIONS FOLLOWING DOUBLE RED CELL (R2) APHERESIS DONATIONS FAVORS USE IN YOUNG DONORS

R.J Benjamin, B.A. Dy, J.M. Kennedy, E. Notari, A.F. Eder (American Red Cross, Washington, D.C., USA)

09.45 – 10.00

4A-S26-03 HAEMOVIGILANCE IN NORDIC COUNTRIES: REPORT OF DONOR COMPLICATIONS 2007

M.R. Abedi, B.S. Sorensen, S. Ekblom-Kullberg, I. Hjálmsdóttir, A. Espinosa (Örebro University Hospital, Örebro, Sweden)

10.00 – 10.15

4A-S26-04 DONOR RETURN RATE IS RELATED TO ADVERSE EVENTS OCCURRING DURING BLOOD DONATION

L. Paesano, M. D'Onofrio, B. Feola, C.C. Caggiano, M. Corvino, A. Di Biase, A. Ciardulli, G. Fratellanza, E. D'Agostino, E. Munno, C. Nocera, S. Misso (PO S.G. Bosco ASL NA1, Napoli, Italy)

10.15 – 10.30

4A-S26-05 PREDICTING THE OCCURRENCE OF VASOVAGAL REACTIONS IN BLOOD DONORS: A QUESTIONNAIRE STUDY BY THE KANAGAWA RED CROSS BLOOD CENTER

S. Inaba, M. Nemoto, Y. Komatsu, H. Watanabe, R. Okubo, T. Rikitake, N. Kinukawa (Kanagawa Red Cross Blood Center, Atsugi, Japan)

SCIENTIFIC PROGRAMME

09.00 – 10.30

Room: Chefren A

S27: Pathogen Inactivation

Moderator: M. Schmidt, J.P. Allain

09.00 – 09.30

4A-S27-01 PATHOGEN REDUCTION METHODS: ADVANTAGES AND LIMITS

H.G. Klein (NIH, Bethesda, MD, USA)

09.30 – 09.50

4A-S27-02 PLATELET CONCENTRATES INACTIVATED BY UVC LIGHT WITHOUT ADDITIONAL PHOTOACTIVE SUBSTANCES MEET STORAGE QUALITY REQUIREMENTS EVEN AFTER SEVEN DAYS OF STORAGE

W. Nussbaumer, M. Hermann, P. Hengster, O. Nussbaumer, H. Schennach, E.M. Amann, R. Halebic (Univ.-Hospital Innsbruck, Innsbruck, Austria)

09.50 – 10.10

4A-S27-03 IMPACT OF PATHOGEN REDUCTION TECHNOLOGY (PRT) WITH MIRASOL_ AND STORAGE IN PLATELET ADDITIVE SOLUTIONS (PAS) ON PLATELET FUNCTION.

A.M. Galan, M. Lozano, P. Molina, F. Navalon, J.M. Rodriguez, S. Marschner, R. Goodrich, G. Escolar (Hospital Clinic. CDB.IDIBAPS.UB, Barcelona, Spain)

10.10 – 10.30

4A-S27-04 A TWO-YEAR EXPERIENCE OF TRANSFUSING PLATELET COMPONENTS PREPARED WITH INTERCEPT PATHOGEN INACTIVATION SYSTEM AND STORED FOR UP TO 7 DAYS

L. Lin, J.C. Osselaer, C. Doyen, L. Defoin, S. Vandenbossche, C. Debry, M. Goffaux, N. Messe, M. Van Hooydonk, J. Hanover, L. Corash (Cliniques Universitaires de Mont Godinne, Universite Catholique de Louvain, Yvoir, Belgium)

SCIENTIFIC PROGRAMME

09.00 – 10.30

Room: Chefren B

S28: Best Poster Session

Moderators: J. Chapman, M. El Ekiaby

The best poster session will consist of 15 short presentations by the authors of the top scoring abstracts not selected for oral presentation. As such this session will cover a wide range of topics. We encourage delegates to come and support the presenters.

11.00 – 10.30

Room: Cheops

Plenary Session

Moderators: E. Seifried, F. Mofteh

TRANSFUSION IN CASUALTIES AND DISASTER SITUATIONS

11.00 – 11.45

4B-PL5 FROZEN RED CELLS, PLASMA AND PLATELETS IN COMBAT CASUALTY CARE

C.C.M. Lelkens, F. Noorman (Military Blood Bank, Leiden, The Netherlands)

HEMOGOLBINOPATHIES, TRANSFUSION AND STEM CELL TRANSPLANTATION

11.45 – 12.30

4B-PL6 STEM CELL TRANSPLANTATION EGYPT

H. Khamel (Egyptian National Blood Transfusion Center, Cairo, Egypt)